You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: BERTEC CORP            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    SBC: ARCHER PHARMACEUTICALS, INC.            Topic: NIA

    Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. O-Glycan-dependent Immunotherapy for Cancer

    SBC: GLYTR THERAPEUTICS, INC.            Topic: 102

    Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery

    SBC: DISCOVERYBIOMED, INC.            Topic: NIDCD

    Principal Investigators for Small BusinessDiscoveryBioMedIncDBMand Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challengesfood insecuritypoor nutritional healthand poor compliance with medication useparticularly among children and the elderlySugar and saltthe mainstays to address these challengesfur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. A novel RF coil and incubator for reducing acoustic noise in neonatal MRI

    SBC: NeoView, Inc.            Topic: NICHD

    PROJECT SUMMARY In this Phase I Small Business Technology TransferSTTRprojecta team of researchers at Cincinnati Childrenandapos s Hospital Medical CenterCCHMCwill work with the engineering team at NeoViewIncto design and build novel body coil and incubator prototypes for aTesla Neonatal Intensive Care UnitNICUMRI systemThese components will play a central role in NeoViewandapos s neonatal MRI pro ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a novel Balloon Occlusion Sheath for Stroke (BOSS)

    SBC: Marblehead Medical LLC            Topic: 106

    PROJECT SUMMARY ABSTRACTThis research program s broadlong term objective is to improve health outcomes for patients suffering fromacute ischemic strokeAISresulting from large vessel occlusionsWe will achieve this purpose by developingimproved access tools for stroke intervention procedureswhich specifically target tool innovations that providesupport for embolectomy devices and arrest flow during ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A NOVEL SELF-ASSEMBLING PROTEIN NANOPARTICLES-BASED GENITAL HERPES VACCINE

    SBC: Sunomix Therapeutics            Topic: NIAID

    ABSTRACTA staggering number of overbillion individuals worldwide are currently infected with herpes simplex virus typeand or typeHSVandampHSVwhich cause genital herpesMost HSV seropositive individuals are asymptomaticASYMPand never have any recurrent herpetic diseaseIn contrasta small proportion is symptomaticSYMPwith frequentoften lifelong bouts of recurrent herpetic diseasea result of reactivati ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Regulation of Autoimmune Type 1 Diabetes by Serpins B1 and A1 (Alpha 1-Antitrypsin)

    SBC: SERPLUS TECHNOLOGY LLC            Topic: 200

    The number of people with diabetes worldwide is predicted to increase frommillion intomillion inThe health care costs of treating the disease account forof the global health expenditure and continue to be a huge economic burdenIDF World AtlasTypediabetes mellitusT DMconstitutesof the disease burdenIt is an autoimmune diseasethought to be triggered by genetic or environmental factors in early child ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke

    SBC: BioTime, Inc.            Topic: 100

    ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading to excessive socioeconomic burdenCell therapy using primary MSCs has been actively explored by us and others as a therapeutic solution to this unmet medical needHoweversince the therapeutic efficacy of ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Nanofiber Expanded CD34+ Stem Cells for Osteoporosis Therapy

    SBC: HNB Therapeutics LLC            Topic: NIA

    Summary Glucocorticoid induced osteoporosis is the most common cause of secondary osteoporosisand the primary cause before ageIt affects overof the general populationwhereinare womenIn postmenopausal women and men agedand overtreatment would be recommended in at least half based on theAmerican College of Rheumatology guidelinesAdult stem cells are a promising class of regenerative cellssome lineag ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government